Houjie M. Liang

Chongqing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 116 publications

First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study.

First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study.

Journal: Advances in therapy

Published: December 04, 2025

Correction: Case Report: Curative effect and mechanism of surufatinib combined with toripalimab in the treatment of 1 case of lung large-cell neuroendocrine carcinoma.

Correction: Case Report: Curative effect and mechanism of surufatinib combined with toripalimab in the treatment of 1 case of lung large-cell neuroendocrine carcinoma.

Journal: Frontiers in oncology

Published: October 22, 2025

The TP53-LGALS4 axis modulates the tumor immune microenvironment and synergizes with anti PD-L1 therapy in colorectal cancer.

The TP53-LGALS4 axis modulates the tumor immune microenvironment and synergizes with anti PD-L1 therapy in colorectal cancer.

Journal: Journal of translational medicine

Published: September 18, 2025

Glutamine-driven upregulation of NPDC1 promotes colorectal cancer progression through PI3K/AKT signaling.

Glutamine-driven upregulation of NPDC1 promotes colorectal cancer progression through PI3K/AKT signaling.

Journal: Journal of translational medicine

Published: August 07, 2025

Heat shock protein family A member 5 regulation of ferroptosis alleviates acute-phase mucosal injury in ulcerative colitis

Heat shock protein family A member 5 regulation of ferroptosis alleviates acute-phase mucosal injury in ulcerative colitis

Journal: Zhonghua nei ke za zhi

Published: July 03, 2025

Hyperglycemia induces an immunosuppressive microenvironment in colorectal cancer liver metastases by recruiting peripheral blood monocytes through the CCL3-CCR1 axis.

Hyperglycemia induces an immunosuppressive microenvironment in colorectal cancer liver metastases by recruiting peripheral blood monocytes through the CCL3-CCR1 axis.

Journal: Journal for immunotherapy of cancer

Published: June 02, 2025

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update.

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update.

Journal: Cancer communications (London, England)

Published: November 27, 2024

Case report: Curative effect and mechanism of surufatinib combined with toripalimab in the treatment of 1 case of lung large-cell neuroendocrine carcinoma.

Case report: Curative effect and mechanism of surufatinib combined with toripalimab in the treatment of 1 case of lung large-cell neuroendocrine carcinoma.

Journal: Frontiers in oncology

Published: November 13, 2024

Epidemiology of biliary tract cancer in China: A narrative review.

Epidemiology of biliary tract cancer in China: A narrative review.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: July 26, 2024

Metabolic-Immune Suppression Mediated by the SIRT1-CX3CL1 Axis Induces Functional Enhancement of Regulatory T Cells in Colorectal Carcinoma.

Metabolic-Immune Suppression Mediated by the SIRT1-CX3CL1 Axis Induces Functional Enhancement of Regulatory T Cells in Colorectal Carcinoma.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: May 01, 2024

NPC1L1 on pancreatic adenocarcinoma cell functions as a two-pronged checkpoint against antitumor activity.

NPC1L1 on pancreatic adenocarcinoma cell functions as a two-pronged checkpoint against antitumor activity.

Journal: Innovation (Cambridge (Mass.))

Published: April 21, 2024

Cancer-associated fibroblasts derived fibronectin extra domain A promotes sorafenib resistance in hepatocellular carcinoma cells by activating SHMT1.

Cancer-associated fibroblasts derived fibronectin extra domain A promotes sorafenib resistance in hepatocellular carcinoma cells by activating SHMT1.

Journal: Genes & diseases

Published: January 22, 2024

Showing 1-12 of 116

Last Updated: 09/26/2026